Open Access

Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records

  • Noboru Kitamura1,
  • Yasuo Takahashi2,
  • Shuukoh Yamadate3 and
  • Satoshi Asai2Email author
Contributed equally
Cardiovascular Diabetology20076:26

https://doi.org/10.1186/1475-2840-6-26

Received: 28 May 2007

Accepted: 29 September 2007

Published: 29 September 2007

Abstract

Background

A beneficial effect on glucose metabolism is reported with angiotensin receptor blocker (ARB) treatment of hypertension. The effect on blood glucose level during the course of treatment with ARBs in clinical cases is uncertain. Our objectives were to survey the changes in glucose and HbA1c levels in patients with hypertension over a one-year period, and to study the correlations between these values and the time after the start of ARB therapy.

Methods

We conducted a retrospective longitudinal survey of blood glucose and HbA1c measurements in Japanese patients aged ≥20 years with newly diagnosed hypertension but without diabetes, who had received ARB monotherapy with candesartan cilexetil, losartan potassium, olmesartan medoxomil, telmisartan, or valsartan during the period from December 2004 to November 2005. Data including 2465 measurements of non-fasting blood glucose in 485 patients and 457 measurements of HbA1c in 155 patients were obtained from electronic medical records of Nihon University School of Medicine. Linear mixed effects models were used to analyze the relationship between these longitudinal data of blood examinations and covariates of patient age, sex, medication, and duration of ARB therapy.

Results

Casual blood glucose level was associated with the duration of treatment (P < 0.0001), but not with age, sex, or medication. Blood glucose level was significantly decreased during the periods of 0~3 months (P < 0.0001) and 3~6 months (P = 0.0081) compared with baseline, but was not significantly different between 6~12 months and baseline. There was no association between HbA1c level and covariates of sex, age, medication and duration of treatment.

Conclusion

Our findings provide new clinical evidence that the effects of ARBs on glucose metabolism may change during the course of treatment, suggesting a blood glucose-lowering effect in the short-term after the start of treatment.

Background

Clinically, there are many cases in which abnormal glucose metabolism and hypertension appear together. Knowing the effects of blood pressure-lowering agents on blood glucose is important for the treatment of hypertensive patients with abnormalities of glucose metabolism or diabetes. The agents most often used for hypertension today include angiotensin receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors, which are both considered to improve glucose metabolism [1, 2]. In addition, much attention has been paid to a prospective clinical trial that showed that ACE inhibitors suppressed the new onset of diabetes [3]. A subsequent report showed that ARBs also suppressed the new onset of diabetes [4]. The magnitude of this effect was around 20–25%. Recent animal experiments have suggested improvement of insulin resistance by ARBs [5, 6]. Clarification of the mechanism of this effect is in progress.

In patients with essential hypertension, plasma insulin and blood glucose levels rise together, indicating reduced insulin sensitivity. Because of this, even without the onset of diabetes, a latent rise in blood glucose level may be seen. We thus selected the study subjects from among those not diagnosed with diabetes at the time of ARB administration, and who were being treated with an ARB alone, at a hospital affiliated to Nihon University School of Medicine, using medical record data for patients who had been diagnosed with hypertension and had received an ARB. We examined the changes in blood glucose and HbA1c levels in these patients over a one-year period, and then studied the correlations between these values and the duration of ARB therapy.

Methods

Study Population

The data for this analysis were collected from a clinical database that integrates information of inpatient and outpatient medical records at a hospital affiliated to Nihon University School of Medicine. The study population consisted of 2635 Japanese men and women aged 20 years or older who had been treated initially by ARB monotherapy at usual doses for at least 4 weeks during the period from December 2004 to November 2005, as shown in Figure 1. Exclusion criteria included treatment with insulin and/or a previous diagnosis of diabetes mellitus according to the Committee for the Classification and Diagnosis of Diabetes Mellitus of the Japan Diabetes Society, defined as fasting plasma glucose level ≥126 mg/dl, casual plasma glucose level ≥200 mg/dl, plasma glucose 2 h after 75 g glucose load ≥200 mg/dl, or hemoglobin A1c (HbA1c) level ≥6.5% [7]. Some patients had received other antihypertensive drugs such as ACE inhibitors or calcium channel blockers during the 2 months before ARB therapy and were excluded from our study. The remaining 1083 patients were subjected to further statistical analysis. The ARBs used are listed in Table 1. Clinical data from the study subjects included sex, age at starting treatment, names of drugs, starting date of treatment, duration of treatment, results of non-fasting blood examination including blood glucose and HbA1c levels, which were determined at the time of routine clinical visits, and date of examination. The blood examination data were collected under the criteria of having at least one value during the 2 months before treatment or the duration of treatment up to a maximum of one year. A total of 485 patients from this population were eligible for the study of blood glucose, and 155 subjects for HbA1c.
Table 1

Angiotensin II receptor blockers

Generic name

Drug name (Trade name)

candesartan cilexetil

Blopress

losartan potassium

Nu-Lotan

olmesartan medoxomil

Olmetec

telmisartan

Micardis

valsartan

Diovan

Figure 1

Flow of study population. Medical record reviews for longitudinal survey data were conducted for 14 months; 2 months before and 12 months during ARB treatment. Detailed criteria for exclusion are described in the Methods.

Statistical Analysis

Our main explanatory variables included sex, age at starting treatment, medication, "duration" defined as the timing of measurement in days since the start of treatment, coded as 0, 1, 2, or 3, with 0 indicating "baseline", i.e., ≤ time 0, and 1, 2, and 3 indicating ">0, ≤3 months", ">3, ≤6 months", and ">6, ≤12 months" since the start of treatment, respectively. Our main response variables were repeated measurements of blood glucose and HbA1c in blood examination before and after treatment with antihypertensive drugs. These data were inherently unbalanced because the number and timing of the repeated measurements were different among individuals. Therefore, linear mixed effects models were used to analyze the relationship between these longitudinal data of blood examination and all other covariates [8]. We fitted random intercept and slope models to the data, including age, sex and medication as fixed effect covariates, and duration of treatment as random effect covariates. A "compound symmetry" covariance was used to covary the random intercept and slopes and estimate the covariance between them. We selected the Kenward-Roger method to compute the denominator degrees of freedom for the tests of fixed effects. A multiple-comparison test (Dunnett-Hsu post-hoc analysis) was used to compare the differences in means between "baseline" as a reference and other times. A result was considered statistically significant if the P value was less than 0.05. All statistical analysis was performed with SAS 9.1.3 (SAS Institute Inc., Cary, NC) statistical software.

Results

Characteristics of study sample

Of the study population of 2635 patients with hypertension who had been treated with ARB monotherapy, a total of 1083 patients without diabetes were subjected to statistical analysis. Blood examination data are shown in Table 2. Approximately 60% of patients were female and 40% were male, for both casual blood glucose and HbA1c measurements. Approximately 65% of patients were aged over 60 years. The numbers of blood examinations were 2465 and 457 for blood glucose and HbA1c, with 5.08 and 2.95 measurements per subject, respectively.
Table 2

Frequency distribution of blood examination data

Variables

Items

Glucose

HbA1c

PATIENT INFORMATION

  

Number of subjects

485

155

Sex

  

   Female

187 (38.6)

54 (34.8)

   Male

298 (61.4)

101 (65.2)

Age, years

  

   20–49

67 (13.8)

20 (12.9)

   50–59

103 (21.2)

33 (21.3)

   60–69

150 (31.0)

47 (30.3)

   70<

165 (34.0)

55 (35.5)

Medication

  

   candesartan cilexetil

177 (36.5)

51 (32.9)

   losartan potassium

78 (16.1)

35 (22.6)

   olmesartan medoxomil

56 (11.5)

21 (13.5)

   telmisartan

56 (11.5)

18 (11.6)

   valsartan

118 (24.3)

30 (19.4)

DATA INFORMATION

  

Number of examinations

2464

457

Treatment duration

  

   0 = "Baseline"

733 (29.8)

150 (32.8)

   1 = "~3 M"

1068 (43.3)

132 (28.9)

   2 = "3~6 M"

377 (15.3)

89 (19.5)

   3 = "6~12 M"

286 (11.6)

86 (18.8)

Abbreviations: HbA1c, hemoglobin A1c. All data are count (percentage).

Relationship of covariates to blood glucose and HbA1c

Table 3 presents the results from linear mixed effect models fitted to casual blood glucose and HbA1c data. There was no association between HbA1c level and any of the covariates of sex, age, medication and "duration of treatment". In contrast to HbA1c, the duration of treatment was associated with blood glucose level. However, sex, age, and medication were not associated with blood glucose level. Our study showed no significant differences in blood glucose and HbA1c levels among the different ARB agents during the time course of ARB therapy. Dunnett's multiple-comparison test showed that blood glucose level was significantly decreased in the periods of "0~3 months" and "3~6 months" compared with "baseline", but was not significantly different between "6~12 months" and "baseline". The interaction of duration of treatment and other covariates was not significant (data not shown). This indicates that the effect of treatment duration does not depend on the level of other covariates. Therefore, the tests for individual effects are valid, showing a significant effect of "treatment duration", but no significant effect of sex, age, and medication. These results indicate that the duration of ARB therapy has an influence on blood glucose level, suggesting a blood glucose-lowering effect of ARBs, at least within 6 months of the start of treatment.
Table 3

Relationship of covariates to blood glucose and HbA1c measurements

Variables

Glucose (mg/dl)

HbA1c (%)

LS mean ± SE

(95% CI)

P value

LS mean ± SE

(95% CI)

P value

Sex

  

0.2268

  

0.8062

   Female

107.80 ± 1.34

(105.15, 110.44)

 

5.51 ± 0.10

(5.31, 5.71)

 

   Male

109.70 ± 1.07

(107.58, 111.81)

 

5.48 ± 0.07

(5.33, 5.64)

 

Age, years

  

0.075

  

0.3041

   20–49

105.09 ± 2.10

(100.96, 109.22)

 

5.33 ± 0.15

(5.01, 5.64)

 

   50–59

108.83 ± 1.75

(105.38, 112.27)

 

5.44 ± 0.13

(5.17, 5.71)

 

   60–69

109.69 ± 1.43

(106.88, 112.51)

 

5.62 ± 0.10

(5.42, 5.83)

 

   70<

111.37 ± 1.32

(108.77, 113.97)

 

5.61 ± 0.09

(5.42, 5.79)

 

Medication

  

0.4579

  

0.6887

   candesartan cilexetil

110.93 ± 1.31

(108.34, 113.51)

 

5.62 ± 0.10

(5.41, 5.82)

 

   losartan potassium

107.73 ± 2.01

(103.77, 111.69)

 

5.52 ± 0.12

(5.28, 5.77)

 

   olmesartan medoxomil

106.99 ± 2.24

(102.58, 111.40)

 

5.37 ± 0.15

(5.06, 5.68)

 

   telmisartan

108.57 ± 2.16

(104.31, 112.83)

 

5.43 ± 0.16

(5.10, 5.76)

 

   valsartan

109.51 ± 1.56

(106.44, 112.59)

 

5.55 ± 0.12

(5.30, 5.81)

 

Treatment duration

  

<.0001

  

0.6014

   0 = "Baseline"

111.98 ± 1.16

(109.70, 114.27)

reference*

5.51 ± 0.07

(5.37, 5.66)

reference*

   1 = "~3 M"

105.86 ± 1.13

(103.64, 108.09)

<.0001*

5.50 ± 0.07

(5.35, 5.65)

0.8209*

   2 = "3~6 M"

107.78 ± 1.48

(104.87, 110.69)

0.0081*

5.44 ± 0.08

(5.28, 5.61)

0.2582*

   3 = "6~12 M"

109.36 ± 1.63

(106.16, 112.56)

0.1308*

5.54 ± 0.08

(5.37, 5.70)

0.7457*

Abbreviations: HbA1c, hemoglobin A1c; LS means, least squares means; SE, standard error; CI, confidence interval.

*Dunnett-Hsu post-hoc analysis.

Discussion

Various opinions exist regarding whether reduction of insulin sensitivity can induce hypertension. Regarding the responsible mechanism, the compensatory high plasma insulin accompanying a reduction of insulin sensitivity is said to: 1) increase sympathetic nerve activity [9], 2) promote renal sodium reabsorption [10], 3) induce the growth of vascular smooth muscle [11], and have other similar effects that induce or aggravate hypertension. On the other hand, hypertension itself may cause sympathicotonia and trigger hyperinsulinemia. Furthermore, each may aggravate the other, producing a vicious cycle of hypertension and high blood glucose.

In the present study, a significant reduction in casual blood glucose level was observed with ARB administration. Regarding the mechanism, the general understanding is that after insulin binds to the insulin receptor, tyrosine phosphorylation inside the cell causes activation of insulin receptor substrate-1 (IRS-1) and phosphatidylinositol 3-kinase (PI3-kinase) [12]. As a result, the rate of glucose uptake into the cell increases. Although insulin resistance itself is still poorly understood, there is evidence that the levels of expression of IRS-3 and PI-3 kinase are reduced, although there may be many other genetic abnormalities involved. Folli et al. showed that, in vascular smooth muscle cells, angiotensin II reduces tyrosine phosphorylation of IRS-1 by approximately 50% and reduces binding of IRS-1 to PI3-kinase by 30–50% [13]. ARB and ACE inhibitors block the inhibitory effect of angiotensin II on insulin signal transmission [3, 4]. As a result, insulin resistance is improved, and there appears to be a beneficial effect on glucose metabolism. ARBs and ACE inhibitors are thought to have the same actions. In the present study, experiments were conducted using ACE inhibitors as well, but the same trends as for ARBs were noted, and no statistically significant difference was observed. The differences between the two could possibly be due to differences in sample size. In addition, ARBs block the effects of angiotensin II at the receptor level, more so than ACE inhibitors. ARBs may thus be more selective in their effects on the renin-angiotensin system.

The effects of ARBs on glucose metabolism have been reported in several experiments on animals and cell lines. Schupp et al. reported that ARBs induce activation of PPAR γ in cultured adipose cell lines of mice, which partially removes insulin resistance [14]. In addition, Fujimoto et al. showed with the same cell line that telmisartan administration increased the uptake of glucose and expression of GLUT4 protein [15]. Furthermore, Furuhashi et al. showed that blocking of the renin-angiotensin system by an ARB increased the plasma adiponectin level [16]. This is hypothesized to be the mechanism by which ARBs reduce blood glucose. However, even in the case of animal experiments, few reports are available concerning how long ARBs affect glucose metabolism. Among clinical trials as well, there are only a few trials, over short time periods and with small numbers of cases.

A particular feature of this study is that it involved a retrospective survey, which included examination of the changes in blood glucose level over time in 485 hypertensive patients with no glucose metabolism abnormalities, spanning 12 months of ARB therapy. In the present study, we observed no statistically significant difference in results among the different ARBs. In addition, our study showed no significant difference in HbA1c level during the time course of ARB therapy. However, patients with diabetes were excluded in the present study, and this may have been the reason for the lack of significant difference in HbA1c level.

Within the first 3 months of ARB therapy, a significant decrease in blood glucose level was noted. This decrease was maintained for 6 months, though blood glucose level subsequently returned to the same level as at the start of administration, and at 12 months, no significant difference from the baseline level was noted. Since blood pressure was controlled from the start of administration, the initial reduction in blood glucose level appears to have been an effect of ARBs and/or the reduction of blood pressure. However, our observation that blood glucose level tended to increase again after 6 months, together with previous reports that thiazide diuretics and β-blockers reduce insulin sensitivity [1719], suggest that the initial reduction in blood glucose appears to have been an effect of ARB treatment.

Limitations

Further study on whether the blood glucose-lowering effect by suppression of the renin-angiotensin system was direct or through some other factor is needed. Although there have been reports that calcium channel blockers and α-blockers improve insulin resistance and glucose metabolism abnormalities, this was not examined in the present study. We are looking into these issues as future subjects of research.

Conclusion

The duration of ARB therapy was significantly associated with casual glucose level in nondiabetic adults with hypertension regardless of treatment with candesartan cilexetil, losartan potassium, olmesartan medoxomil, telmisartan, or valsartan. Our findings not only support the notion that ARBs can improve glucose metabolism via blocking the inhibitory effect of angiotensin II on insulin signal transmission as suggested elsewhere, but also demonstrate that the effects of ARBs on glucose metabolism are associated with the course of treatment, suggesting a blood glucose-lowering effect within 6 months of the start of ARB therapy.

Notes

Declarations

Acknowledgements

This work was supported in part by a Grant-in Aid from the Japanese Ministry of Education, Science, Sports and Culture to promote advanced scientific research, awarded to Nihon University.

Authors’ Affiliations

(1)
Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine
(2)
Division of Genomic Epidemiology and Clinical Trials, Advanced Medical Research Center, Nihon University School of Medicine
(3)
Clinical Laboratory, Nihon University Nerima-Hikarigaoka Hospital

References

  1. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP: Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest. 1997, 100 (9): 2158-2169.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Folli F, Saad MJ, Velloso L, Hansen H, Carandente O, Feener EP, Kahn CR: Crosstalk between insulin and angiotensin II signalling systems. Exp Clin Endocrinol Diabetes. 1999, 107 (2): 133-139.View ArticlePubMedGoogle Scholar
  3. Fujimoto M, Masuzaki H, Tanaka T, Yasue S, Tomita T, Okazawa K, Fujikura J, Chusho H, Ebihara K, Hayashi T: An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes. FEBS Lett. 2004, 576 (3): 492-497. 10.1016/j.febslet.2004.09.027.View ArticlePubMedGoogle Scholar
  4. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N, Yoshida D, Shimamoto K: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003, 42 (1): 76-81. 10.1161/01.HYP.0000078490.59735.6E.View ArticlePubMedGoogle Scholar
  5. Haenni A, Lithell H: Treatment with a beta-blocker with beta 2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism. 1994, 43 (4): 455-461. 10.1016/0026-0495(94)90076-0.View ArticlePubMedGoogle Scholar
  6. Kaplan NM: Effects of antihypertensive therapy on insulin resistance. Hypertension. 1992, 19 (1 Suppl): I116-118.View ArticlePubMedGoogle Scholar
  7. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M, Nanjo K, Sasaki A, Seino Y, Ito C: Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract. 2002, 55 (1): 65-85. 10.1016/S0168-8227(01)00365-5.View ArticlePubMedGoogle Scholar
  8. Fitzmaurice GM, Laird NM, Ware JH: Applied longitudinal analysis. 2004, New York: John Wiley & Sons, IncGoogle Scholar
  9. Landsberg L: Insulin sensitivity in the pathogenesis of hypertension and hypertensive complications. Clin Exp Hypertens. 1996, 18 (3–4): 337-346.View ArticlePubMedGoogle Scholar
  10. Landsberg L: Insulin-mediated sympathetic stimulation: role in the pathogenesis of obesity-related hypertension (or, how insulin affects blood pressure, and why). J Hypertens. 2001, 19 (3 Pt 2): 523-528. 10.1097/00004872-200103001-00001.View ArticlePubMedGoogle Scholar
  11. Lithell H, Pollare T, Vessby B: Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press. 1992, 1 (2): 92-101.View ArticlePubMedGoogle Scholar
  12. Okada K, Hirano T, Ran J, Adachi M: Olmesartan medoxomil, an angiotensin II receptor blocker ameliorates insulin resistance and decreases triglyceride production in fructose-fed rats. Hypertens Res. 2004, 27 (4): 293-299. 10.1291/hypres.27.293.View ArticlePubMedGoogle Scholar
  13. Paolisso G, Gambardella A, Verza M, D'Amore A, Sgambato S, Varricchio M: ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients. J Hum Hypertens. 1992, 6 (3): 175-179.PubMedGoogle Scholar
  14. Ran J, Hirano T, Fukui T, Saito K, Kageyama H, Okada K, Adachi M: Angiotensin II infusion decreases plasma adiponectin level via its type 1 receptor in rats: an implication for hypertension-related insulin resistance. Metabolism. 2006, 55 (4): 478-488. 10.1016/j.metabol.2005.10.009.View ArticlePubMedGoogle Scholar
  15. Scheen AJ: Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab. 2004, 30 (6): 498-505. 10.1016/S1262-3636(07)70147-7.View ArticlePubMedGoogle Scholar
  16. Scheen AJ: Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system. Drugs. 2004, 64 (22): 2537-2565. 10.2165/00003495-200464220-00004.View ArticlePubMedGoogle Scholar
  17. Scheen AJ: Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab. 2004, 30 (6): 487-496. 10.1016/S1262-3636(07)70146-5.View ArticlePubMedGoogle Scholar
  18. Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, Hennuyer N, Ruiz P, Unger T, Staels B: Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity. Diabetes. 2005, 54 (12): 3442-3452. 10.2337/diabetes.54.12.3442.View ArticlePubMedGoogle Scholar
  19. Weir MR, Dzau VJ: The renin-angiotensin-aldosterone system: a specific target for hypertension management. Am J Hypertens. 1999, 12 (12 Pt 3): 205S-213S. 10.1016/S0895-7061(99)00103-X.View ArticlePubMedGoogle Scholar

Copyright

© Kitamura et al; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.